公开(公告)号：EP2167502B3

公开(公告)日：2013-07-10

申请号：EP08779348.5

申请日：2008-06-05

申请人： AstraZeneca AB

发明人： CLAYTON, Joshua ,  EGLE, Ian ,  EMPFIELD, James ,  FOLMER, James ,  ISAAC, Methvin ,  MA, Fupeng ,  SLASSI, Abdelmalik

IPC分类号： C07D487/08 ,  C07D413/04

CPC分类号： C07D413/04 ,  C07D413/14 ,  C07D487/08

公开(公告)号：EP2601177A1

公开(公告)日：2013-06-12

申请号：EP11746295.2

申请日：2011-08-05

申请人： AstraZeneca AB

发明人： DIEBOLD, Robert Bruce ,  GERO, Thomas ,  GROVER, Paul ,  HUANG, Shan ,  IOANNIDIS, Stephanos ,  OGOE, Claude Afona ,  SAEH, Jamal Carlos ,  VARNES, Jeffrey Gilbert

IPC分类号： C07D211/22 ,  A61K31/445 ,  A61P35/00 ,  A61P35/02

CPC分类号： C07F9/65583 ,  A61K31/451 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/675 ,  C07D211/22 ,  C07D211/34 ,  C07D413/12 ,  C07F9/58 ,  C07F9/59 ,  C07F9/650952

摘要： The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-X
L activities and may be used for the treatment of cancer.

摘要翻译： 本发明涉及式（I）化合物及其盐，药物组合物，使用方法及其制备方法。 这些化合物抑制Bcl-2和/或Bcl-XL活性，并可用于治疗癌症。

公开(公告)号：EP2574188A1

公开(公告)日：2013-04-03

申请号：EP11783835.9

申请日：2011-05-19

申请人： Targacept, Inc. ,  AstraZeneca AB

发明人： DULL, Gary Maurice ,  GENUS, John ,  RATILAINEN, Tommi ,  RYBERG, Per Olof ,  HELLSTRÖM, Janna ,  WAHLSTRÖM, Niklas ,  WÄNNMAN, Thomas

IPC分类号： C07C29/40 ,  C07C211/21 ,  C07C231/14 ,  C07D213/65

CPC分类号： C07D213/65 ,  C07C29/36 ,  C07C211/21 ,  C07C269/04 ,  C07C33/03 ,  C07C271/12

摘要： An improved process for the preparation of aryl substituted olefinic amines such as (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine and (2S)-(4E)-N- methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine and new intermediates used in said process.

公开(公告)号：EP1303496B1

公开(公告)日：2007-09-12

申请号：EP01947671.2

申请日：2001-07-06

申请人： AstraZeneca AB

发明人： THOMAS, Andrew Peter ,  NEWCOMBE, Nicholas John ,  HEATON, David William

IPC分类号： C07D239/48

CPC分类号： C07D239/48 ,  A61K31/505 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12

摘要： Compounds of formula (I), wherein R?1, p, R2, q, R3 and R4¿ are defined within, and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

公开(公告)号：EP2391606A1

公开(公告)日：2011-12-07

申请号：EP09835355.0

申请日：2009-12-22

申请人： AstraZeneca AB

发明人： BALESTRA, Michael ,  BERNSTEIN, Peter ,  ERNST, Glen, E ,  FRIETZE, William ,  MCCAULEY, John P ,  NUGIEL, David ,  SHEN, Lihong

IPC分类号： C07D213/38 ,  A61K31/4402 ,  A61P25/24

CPC分类号： C07D213/38 ,  A61K31/4402 ,  C07C57/15

摘要： The present invention relates to ethanamine compounds, namely 1- (3-f luorophenyl) -2-methyl-2- (pyridine-2-yl) propan-1-amine and 2-methyl-l-phenyl-2- (pyridine-2yl) propan-1-amine, the enantiomers and salts thereof and their use for the treatment of depression.

公开(公告)号：EP2303872A1

公开(公告)日：2011-04-06

申请号：EP09758630.9

申请日：2009-06-08

申请人： AstraZeneca AB

发明人： CACCIOLA, Joseph ,  EMPFIELD, James ,  FOLMER, James ,  HUNTER, Angela M ,  THRONER, Scott

IPC分类号： C07D413/10 ,  A61K31/422 ,  A61P25/00 ,  C07D209/46

CPC分类号： A61B17/083 ,  A61B17/085 ,  A61B17/10 ,  A61B17/105 ,  C07D413/04

摘要： Compounds in accord with Formula (I): wherein R
1 , R
2 , R
3 and R
4 arc as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

公开(公告)号：EP2061784A1

公开(公告)日：2009-05-27

申请号：EP07804279.3

申请日：2007-09-12

申请人： AstraZeneca AB

发明人： BUTTERWORTH, Sam ,  GRIFFEN, Edward, Jolyon ,  PASS, Martin

IPC分类号： C07D401/14

CPC分类号： C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14

摘要： The invention concerns pyrimidine derivatives of Formula (I), wherein each of p, R1, R2, q, R3, r, R4, X1 and Q1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in a method for producing an anti-proliferative effect in a warm blooded animal such as man.

公开(公告)号：EP2029593A1

公开(公告)日：2009-03-04

申请号：EP07732879.7

申请日：2007-05-18

申请人： AstraZeneca AB

发明人： FOOTE, Kevin, Michael ,  GRIFFEN, Edward, Jolyon

IPC分类号： C07D471/04 ,  A61K31/4162 ,  A61K31/437 ,  A61P31/00

CPC分类号： C07D471/04

摘要： The invention concerns indole derivatives of Formula (I) or pharmaceutically-acceptable salts thereof, wherein each of Ring A, m, R1, R2, n, R3 and G1 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.

摘要翻译： 本发明涉及式（I）的吲哚衍生物或其药学上可接受的盐，其中环A，m，R1，R2，n，R3和G1中的每一个具有上文在说明书中定义的任何含义; 其制备方法，含有它们的药物组合物以及它们在治疗中的用途，例如治疗由PI3K酶和/或mTOR激酶介导的疾病。

公开(公告)号：EP1345918B1

公开(公告)日：2007-04-18

申请号：EP01271366.5

申请日：2001-12-17

申请人： AstraZeneca AB

发明人： STARKE, Ingemar ,  DAHLSTROM, Mikael ,  BLOMBERG, David

IPC分类号： C07D281/10 ,  C07D417/12 ,  C07F9/6536 ,  C07K5/065 ,  C07K5/087 ,  A61K31/554 ,  A61K31/675 ,  A61K38/05 ,  A61K38/06 ,  A61P3/06

CPC分类号： C07D417/12 ,  A61K45/06 ,  C07D281/10 ,  C07F9/6536

摘要： The present invention relates to compounds of the formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.

公开(公告)号：EP1427718A1

公开(公告)日：2004-06-16

申请号：EP02765012.6

申请日：2002-09-05

申请人： AstraZeneca AB

发明人： STARKE, Ingemar ,  DAHLSTROM, Mikael, Ulf, Johan ,  BLOMBERG, David

IPC分类号： C07D337/08 ,  C07D409/12 ,  A61K31/38 ,  A61P3/06

CPC分类号： C07D409/12 ,  C07D337/08

摘要： The present invention relates to compounds of formula (I) wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.